Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26026727 | 0.88 | SMN1; SMN2 (0.38) | SIRT1SIRT2PDFCA1CA2 | |
| SCHEMBL29649566 | 0.88 | SMN1; SMN2 (0.38) | SIRT1SIRT2PDFCA1CA2 | |
| SCHEMBL29649455 | 0.85 | SIRT1 (0.37) | SIRT1SIRT2KDM4EMAPTNPSR1 | |
| SCHEMBL26026882 | 0.84 | LTA4H (0.45) | LTA4H | |
| SCHEMBL26027084 | 0.80 | KLKB1 (0.51) | SIRT1HTTMAPTKLKB1KMT2A | |
| SCHEMBL17805765 | 0.78 | KLKB1 (0.40) | CA1CA2HTTKDM4EMAPT | |
| SCHEMBL26026941 | 0.78 | FURIN (0.35) | FURIN | |
| SCHEMBL16392367 | 0.77 | SPHK1 (0.40) | KLKB1FURIN | |
| SCHEMBL16847756 | 0.77 | SPHK1 (0.40) | KLKB1FURIN | |
| SCHEMBL16424794 | 0.76 | CA1 (0.47) | SIRT1SIRT2CA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SIRT1 2353/4885SIRT2 2798/4885PDF 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.